{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:13:11Z","timestamp":1753877591090,"version":"3.41.2"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T00:00:00Z","timestamp":1507334400000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment of Legionnaires\u2019 disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.<\/jats:p>","DOI":"10.1093\/ofid\/ofx184","type":"journal-article","created":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T13:29:04Z","timestamp":1507382944000},"source":"Crossref","is-referenced-by-count":7,"title":["Tigecycline as a Second-Line Agent for Legionnaires\u2019 Disease in Severely Ill Patients"],"prefix":"10.1093","volume":"4","author":[{"given":"Deepika","family":"Slawek","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, NYU Langone Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Altshuler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanina","family":"Dubrovskaya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie","family":"Louie","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, NYU Langone Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,7]]},"reference":[{"key":"2020081005190305500_CIT0001","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1093\/cid\/civ157","article-title":"The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia","volume":"60","author":"Gershengorn","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081005190305500_CIT0002","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199709043371006","article-title":"Legionellosis","volume":"337","author":"Stout","year":"1997","journal-title":"N Engl J Med"},{"key":"2020081005190305500_CIT0003","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1128\/CMR.15.3.506-526.2002","article-title":"Legionella and Legionnaires\u2019 disease: 25 years of investigation","volume":"15","author":"Fields","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"2020081005190305500_CIT0004","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1093\/clind\/21.Supplement_3.S265","article-title":"Antimicrobial chemotherapy for legionnaires\u2019 disease: a review","volume":"21","author":"Edelstein","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2020081005190305500_CIT0005","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14656560902900820","article-title":"Treatment strategies for Legionella infection","volume":"10","author":"Pedro-Botet","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"2020081005190305500_CIT0006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.47.2.533-540.2003","article-title":"Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia","volume":"47","author":"Edelstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081005190305500_CIT0007","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2010.08.023","article-title":"Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages","volume":"69","author":"Bopp","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081005190305500_CIT0008","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1179\/1120009X12Z.00000000022","article-title":"Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections","volume":"24","author":"Tek\u00e7e","year":"2012","journal-title":"J Chemother"},{"key":"2020081005190305500_CIT0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/00365540903359895","article-title":"Disseminated Legionella pneumophila infection in an immunocompromised patient treated with tigecycline","volume":"42","author":"Valve","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"2020081005190305500_CIT0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/AAC.30.5.743","article-title":"Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents","volume":"30","author":"Vild\u00e9","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081005190305500_CIT0011","first-page":"61","article-title":"A case of legionellesis pneumonia verified by isolation of Legionella pneumophila serogroup 1 from bronchoalveolar lavage fluid treated with levofloxacine and tigecycline","volume":"83","author":"Galstian","year":"2011","journal-title":"Ter Arkh"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/4\/ofx184\/33624038\/ofx184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/4\/ofx184\/33624038\/ofx184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T09:27:10Z","timestamp":1597051630000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofx184\/4372228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofx184","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2017]]},"published":{"date-parts":[[2017]]},"article-number":"ofx184"}}